Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Having the privilege of info from multiple sources that attended the AGM today what I am really pleased about (beyond the substance of the AGM on itself) is just about all the positive statements, answers to questions etc have been corroborated by more than one source. Cheers to all that attended and shared in good faith. Whatever board they are posting on.
Doc83, unfortunately, no I wasn't there but patiently waiting to read your posts, thank you, also pleased that you feel more positive, hopefully that will rub off onto all of us!! Will be interesting reading the feedback later, take care all.
Just adding thanks, whilst inbetween flights, to all those taking the time to confer and get notes typed up. Really wanted to be there, so not laziness on my part so, like others on here, very grateful for the effort that is going on to give us the PI view.
Thanks to all who attended.
Looking forward to the feedback.
Doc83
It is really good to hear that PI's were given a proper and respectful opportunity
to raise their concerns.... Looking forward to the detail...Cheers!
Tommy - I think that’s a very fair assessment. It went on until around 11.15am, with most of that for Q&A for those in the room…. Got to give them full credit for that. They were peppered non stop with questions and I thought answered most of them well. A few responses I particularly liked, and I tend to agree that Synairgen’s future is far from done.
Reversal of the drop pre the AGM is a good sign and everything I’m hearing suggests a positive AGM with the BOD more than willing to engage with all questions and with open and honest answers.
Also some interesting positive thoughts which I’m sure those who attended will share in detail over the coming days.
A good day for shareholders and I think it’s fair to say the impression from the BOD is Synairgen’s future this is far from over.
A big RNS tomorrow and we went over a £ and then I woke up
Reworded question for Doc83 or others to ask at AGM:
Due to the significant share placing and cost to employ leading trial coordinators, are you satisfied with their trial performance and level of protocol violations? If not, have you asked and been provided adequate reasons and is compensation a possibility to fund an add-on retrial in order to continue the objective of an independent trial to accomplish the true value of Synairgen.
Please amend if appropriate.
You don’t ask, you don’t get. If asked at the AGM, they would need to answer (& then hopefully act) unlike if sent by email.
Just would be good to encourage this option to avoid SNG running out of money, or being at the mercy of JV’s or cheap take over if its dragged out. The possibility of a funded retrial would jump the share price again and a smaller quicker trial to bulk up the figures could provide a quicker approval than alternative options.
Good luck all
Thanks to all who have offered to give some feedback from the AGM..MUCH appreciated !!
M.
Forget even......!
Now Wigster..... Forgret flirting with Maud ... We want you listening to every word
and require a detailed report on here by 11am SHARP !!!! LOL!
Look forward to hearing the feedback....Hoping there is some unexpected
gem to give us all a lift.... ATB and thanks !!!
I think you're right Doc. I'm going tomorrow; more out of interest than anything - certainly my expectation bar is set very low...if I get a nice cup of Maud's tea I'll be happy.
Cmww2014 - will take some notes if I can (and if I remember my pen).
If anyone clocks someone from Polygon, start chatting!
*if anyone is able to share notes
If Synairgen were a biscuit, what sort of biscuit would it be?
That'd get to the bottom of the situation once and for all !
My bet would be a rich tea. Nothing really wrong with the taste though unloved so perhaps destined to go stale in the barrel ?
Bit seriously I fanzine is able to take notes tomorrow/ share the 'best bits' it would be great
Niceday - realistically, how else can they answer that but “yes”?!
Q. Does the current BoD believe they have the ambition and expertise to bring the drug to market and achieve commercial sales?
Doc83
I do not think we have all of the results in yet, so cannot determine our position..
We really need to know ACTIV 2 numbers and is P3 confirmed..
Also the Long Covid from SPRINTER, and some detail on discussions for
a Platform trial..... The above could vastly change our fortunes...!!
Manifesto - yes, we would really need two or more potential partners fighting over us. Because if not, I maintain our position is weak. MrCosts is right… we are now reliant on others, and that is usually not a good place to find yourself.
surprised....
Doc83
I would hope that we are a prime target for a JV ... The potential
here is not diminished by the SPRINTER flaws.... I would
be very surprisd if there is only one interested party at the table....! ATB!
It is most likely that tomorrow will be a non event, and as a result the SP could fall (it already is!).
But we know we are waiting for news on ACTIV P2 data and new trials. So if there's no news tomorrow we shouldn't necessarily panic. What I'm really after tomorrow is to find out if the current management team have the ability to take Synairgen forward and what their own plans/thoughts are for the future.
Tommy says questions about money running out are being answered by the BOD saying they'll JV/partner up. But as mentioned earlier, we seem in a very weak position to be negotiating any JV terms. Any partner who don't like our terms can tell us to go on our own, knowing we can't afford it. I may be wrong...
I think I've seen evidence on other boards that some PR/communications firms regularly monitor these discussions. So hopefully they'll have some answers already prepared in advance.
I am managing my expectations yet again .All we can expect as positive news is another trial and a peer review publication Just reading this article on long COVID on a small study by NIAID in long COVID patients "Plasma and blood samples from a subgroup of participants were analyzed by scientists for levels of various inflammatory biomarkers, as well as markers of lymphocyte activation. These studies did not find evidence of abnormal activation of the immune system in people with long COVID. "
Its disappointing they did not find evidence of type 1 autoantibodies in these patients
Now Activ 2 blood samples were taken but not in P3 We still awaiting for the Activ 2 data and P3 long COVID investigations to offer a glimmer of hope
https://www-novarnish.niaid.nih.gov/news-events/niaid-study-focuses-long-covid-symptoms